The Newsroom of Immunophotonics, Inc.

Immunophotonics, Inc. Press Releases

  • Published on April 6, 2022 - 15:30 GMT

    Immunophotonics Raises $21.4 Million in Equity Financing for Phase 2 Clinical Trials

    ST. LOUIS, MISSOURI, AND BERN, SWITZERLAND, April 6, 2022 /⁨EINPresswire.com⁩/ -- Immunophotonics, Inc., a clinical-stage biotech company focused on the discovery and development of novel immune-activating drugs in oncology and infectious disease, continues to attract investments that will fund research and clinical trials regarding the use of the company’s lead drug candidate, IP-001. The latest financing tranche, which was raised through the sale of the company’s authorized Series B Preferred Stock, has …

    Distribution channels: Banking, Finance & Investment Industry, Business & Economy ...
  • Published on February 17, 2022 - 19:52 GMT

    Immunophotonics Awarded $2.4 Million SBIR Grant by the National Cancer Institute

    ST. LOUIS, MISSOURI, UNITED STATES, February 17, 2022 /⁨EINPresswire.com⁩/ -- Immunophotonics, Inc., a clinical-stage biotech company, was recently awarded a Small Business Innovative Research (SBIR) Phase I / Phase II Fast-Track grant for $2.4 million for research regarding use of the company’s lead drug candidate, IP-001. The research will assess the potential of IP-001 when administered in conjunction with microwave thermal ablation in HCC liver cancer, further expanding the potential clinical …

    Distribution channels: Business & Economy, Companies ...
Contact
Public Relations
Immunophotonics, Inc.
+1 314-501-1919
Share This Newsroom
Company/Organization
Immunophotonics, Inc.
4340 Duncan Avenue, Suite 212
Saint Louis, Missouri, 63110
United States
+1 314-501-1919
Visit Website
About

Immunophotonics is a privately owned clinical-stage biotech company that is pioneering the burgeoning field of Interventional Immuno-Oncology® through the development of novel treatments for solid-tumor cancers. IP-001, the first asset from the company’s intellectual property platform, has the potential to transform a routine tumor ablation into a systemically active cancer immunotherapy. Immunophotonics is also exploring the use of its technology platform to help prevent and combat contractions of infectious diseases. Immunophotonics is headquartered in St. Louis, Missouri, with a subsidiary in Bern, Switzerland.